Eli Lilly breaks ground on $3.5 billion Pennsylvania plant for obesity drugs

Eli Lilly started building a $3.5 billion Lehigh Valley plant meant to make next-generation obesity injectables by 2031.

Objective Facts

Eli Lilly broke ground on November 12, 2026, on a $3.5 billion plant in Fogelsville, in Pennsylvania's Lehigh Valley, according to a company release and Gov. Josh Shapiro's office. The roughly 925,000-square-foot complex will produce injectable medicines and devices, with a focus on next-generation obesity treatments such as retatrutide, an investigational drug Lilly has not yet submitted for U.S. approval. Lilly expects about 850 permanent jobs and 2,000 construction jobs, and the facility is scheduled to begin operating in 2031. Shapiro's office said the state committed about $100 million in grants and proposed tax credits, plus up to $5 million for a training program at Lehigh Carbon Community College. The project was first announced in January 2026 and is Lilly's first manufacturing site in Pennsylvania.

Deep Dive

Lilly first named the Lehigh Valley site in January 2026, as AP reported at the time, and returned this week with shovels and state officials. The company's release frames the plant as preparation for possible large-scale production of retatrutide, a once-weekly injection that targets three hormone receptors (GIP, GLP-1 and glucagon). Construction Review Online reported that Lilly plans to file a Biologics License Application for retatrutide in the first quarter of 2027 and that peak construction should run from late 2027 into early 2029, with up to 1,500 workers on site at a time. Lilly CEO David Ricks said in the release that the science of treating obesity "is moving quickly." The public money is significant. Shapiro's office listed $50 million in proposed PA Edge tax credits, a $25 million PA SITES grant, a $25 million Pennsylvania First grant and up to $5 million in state capital funds for workforce training. It also said the state Department of Environmental Protection approved a stormwater permit in 47 days through its fast-track program. WFMZ's report relied mostly on the governor's remarks and did not include resident reaction or detail on traffic, water use or other local effects, and none of the coverage reviewed for this story examined the subsidy terms or job guarantees in depth. Lilly also pledged up to $1 million over five years to the Upper Macungie Township Community Fund. The main open question is timing. The plant is built around a drug that is not yet approved, and the site will not run until 2031, so its output depends on how retatrutide fares with regulators. Watch for the planned 2027 filing, Lilly's hiring through Lehigh Carbon Community College, and whether the state's incentive package carries performance requirements tied to the 850 jobs. Lehigh Valley Economic Development Corp. chief Don Cunningham called it "the largest economic development project in Lehigh Valley history," in a state release.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

Eli Lilly breaks ground on $3.5 billion Pennsylvania plant for obesity drugs

Eli Lilly started building a $3.5 billion Lehigh Valley plant meant to make next-generation obesity injectables by 2031.

Nov 13, 2026
What's Going On
  • Eli Lilly and Pennsylvania Gov. Josh Shapiro broke ground on Thursday, November 12, 2026, on a $3.5 billion manufacturing site in Fogelsville, Upper Macungie Township, Lehigh County.
  • The plant will make injectable medicines and devices, including the investigational once-weekly obesity drug retatrutide, which is still in Phase 3 trials and not approved for sale.
  • Lilly said the site will employ about 850 permanent workers and support roughly 2,000 construction jobs, with operations expected to start in 2031.
  • Shapiro's office said the state is putting about $100 million toward the project, including $50 million in proposed PA Edge tax credits and two $25 million grants.
  • Lilly said the site is one of 10 new U.S. plants it has announced since 2020 under a $50 billion domestic manufacturing push.
◆ All Sources (8)
PR Newswire (Eli Lilly) - Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicinesPennsylvania Governor's Office - Gov. Shapiro Breaks Ground on Lilly's Pharmaceutical Manufacturing FacilityPA DCED - In Lehigh County, Governor Shapiro Breaks Ground on Lilly's Historic $3.5 Billion Pharmaceutical Manufacturing FacilityWFMZ - Eli Lilly breaks ground on $3.5B manufacturing facility in Lehigh CountyChain Drug Review - Lilly breaks ground on $3.5B Pennsylvania facilityConstruction Review Online - Eli Lilly Breaks Ground on $3.5B Pennsylvania Drug Manufacturing FacilityRTTNews - Eli Lilly Breaks Ground On Pennsylvania Manufacturing Facility, To Begin Operations In 2031WTOP (AP) - Drugmaker Eli Lilly announces new plant in Pennsylvania as part of broader domestic expansion
Objective Deep Dive

Lilly first named the Lehigh Valley site in January 2026, as AP reported at the time, and returned this week with shovels and state officials. The company's release frames the plant as preparation for possible large-scale production of retatrutide, a once-weekly injection that targets three hormone receptors (GIP, GLP-1 and glucagon). Construction Review Online reported that Lilly plans to file a Biologics License Application for retatrutide in the first quarter of 2027 and that peak construction should run from late 2027 into early 2029, with up to 1,500 workers on site at a time. Lilly CEO David Ricks said in the release that the science of treating obesity "is moving quickly."

The public money is significant. Shapiro's office listed $50 million in proposed PA Edge tax credits, a $25 million PA SITES grant, a $25 million Pennsylvania First grant and up to $5 million in state capital funds for workforce training. It also said the state Department of Environmental Protection approved a stormwater permit in 47 days through its fast-track program. WFMZ's report relied mostly on the governor's remarks and did not include resident reaction or detail on traffic, water use or other local effects, and none of the coverage reviewed for this story examined the subsidy terms or job guarantees in depth. Lilly also pledged up to $1 million over five years to the Upper Macungie Township Community Fund.

The main open question is timing. The plant is built around a drug that is not yet approved, and the site will not run until 2031, so its output depends on how retatrutide fares with regulators. Watch for the planned 2027 filing, Lilly's hiring through Lehigh Carbon Community College, and whether the state's incentive package carries performance requirements tied to the 850 jobs. Lehigh Valley Economic Development Corp. chief Don Cunningham called it "the largest economic development project in Lehigh Valley history," in a state release.

◈ Tone Comparison

Coverage of the groundbreaking was almost uniformly celebratory and drew heavily on official statements. Shapiro called it "the biggest life sciences investment in our commonwealth's history," in remarks reported by WFMZ, while Republican U.S. Sen. Dave McCormick, quoted in Lilly's release, focused on "850 high-paying jobs" and American manufacturing. Trade outlets such as Construction Review Online and RTTNews kept to construction schedules, jobs and the retatrutide pipeline.